Avanir Pharmaceuticals (AVNR)
Avanir Pharmaceuticals Revenue Growth: 598.9%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AVNR Revenue Growth Rankings
| Overall | 99th percentile | 27 of 4358 |
| Sector | 96th percentile | 14 of 456 in Healthcare |
| Industry | 90th percentile | 1 of 11 in Drugs - Generic |
AVNR Revenue Growth Range, Past 5 Years
| Minimum | -99.84% | Jun 2008 |
| Maximum | 16314% | Jun 2009 |
| Average | 970.4% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AVNR related companies
AVNR News
Avanir Pharmaceuticals CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
May 17, 5:16PM Seeking Alpha
May 17, 5:16PM Seeking Alpha
$AVNR forms bullish "Continuation Wedge" chart pattern. http://stks.co/3mTw
about 17 days ago by RecogniaEvents
about 17 days ago by RecogniaEvents
$AVNR 200 Day SMA Cross - Price crossed above 200 day SMA (2.8357). Confirmed by volume.
about 17 days ago by TradeIdeasQuant
about 17 days ago by TradeIdeasQuant
Avanir Pharmaceuticals' Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript)
May 09, 11:17PM Seeking Alpha
May 09, 11:17PM Seeking Alpha
Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Nuedexta Trajectory Holding Steady
May 09, 9:49AM Street Insider
May 09, 9:49AM Street Insider
$AVNR 200 Day SMA Cross - Price crossed above 200 day SMA (2.8471). Confirmed by volume.
about 19 days ago by TradeIdeasQuant
about 19 days ago by TradeIdeasQuant
Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript
May 08, 3:11PM Seeking Alpha
May 08, 3:11PM Seeking Alpha
Listen to $AVNR at deutsche bank ag health care conference - live at 02:50 PM, ondemand after - http://stks.co/3j5b
about 19 days ago by earningscast
about 19 days ago by earningscast
Listen to $AVNR Q2 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3iVG
about 19 days ago by earningscast
about 19 days ago by earningscast
Avanir Pharmaceuticals Reports Fiscal 2012 Second Quarter Financial and Business Results
May 08, 8:30AM PR Newswire
May 08, 8:30AM PR Newswire
Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
May 01, 8:30AM PR Newswire
May 01, 8:30AM PR Newswire
$AVNR forms bullish "Bottom Triangle" chart pattern. http://stks.co/3W9S
about 32 days ago by RecogniaEvents
about 32 days ago by RecogniaEvents
Listen to $AVNR at biocentury & thomson reuters future leaders in the biotech in - live at 10:00 AM, ondemand after - http://stks.co/3Qz9
about 37 days ago by earningscast
about 37 days ago by earningscast
$AVNR 200 Day SMA Cross - Price crossed above 200 day SMA (2.8803). Confirmed by volume.
about 38 days ago by TradeIdeasQuant
about 38 days ago by TradeIdeasQuant
Seekingalpha article Science v HedgeFund http://stks.co/3NzD
Here is a link to the deleted article. $ARNA $CHTP $DNDN $AVNR $VVUS
about 40 days ago by Montisumo
about 40 days ago by Montisumo
Avanir Pharmaceuticals to Present Data at the American Academy of Neurology Annual Meeting
Apr 17, 8:30AM PR Newswire
Apr 17, 8:30AM PR Newswire
Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Apr 10, 8:30AM PR Newswire
Apr 10, 8:30AM PR Newswire
$AVNR is 5.1% up since open on unusual high volume and 3.8% up since close.
about 68 days ago by TradeBot
about 68 days ago by TradeBot
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Mar 16, 8:30AM Benzinga
Mar 16, 8:30AM Benzinga
Cell Therapeutics and Avanir Pharmaceuticals Look to Make Headway in Strengthening Biotech Industry
Mar 12, 8:20AM Marketwire
Mar 12, 8:20AM Marketwire
$AVNR $BLK $BLDR Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying | http://stks.co/2jPW
about 80 days ago by Benzinga
about 80 days ago by Benzinga
Avanir's CEO Presents at Citi 2012 Global Health Care Conference - Transcript
Feb 29, 1:48PM Seeking Alpha
Feb 29, 1:48PM Seeking Alpha
$AVNR http://stks.co/2ZP7 Could be bouncing off support zone and ready to move higher again
about 90 days ago by fornix
about 90 days ago by fornix
Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
Feb 21, 9:15AM PR Newswire
Feb 21, 9:15AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AVNR | 2.84 | +0.02 | +0.71% | 376.87M |
| AVL | 1.45 | -0.01 | -0.68% | |
| AVK | 15.28 | +0.01 | +0.07% | |
| AVII | 0.7185 | -0.01 | -1.58% | 97.53M |
| AVID | 6.68 | -0.11 | -1.62% | 258.45M |
| AVGO | 33.15 | +0.64 | +1.97% | 8.085B |
| AVEO | 12.60 | +0.41 | +3.36% | 544.95M |
| AVD | 25.75 | -0.01 | -0.04% | 710.96M |
| AVCA | 6.199 | +0.26 | +4.36% | 36.08M |
| AVB | 139.84 | -1.30 | -0.92% | 13.31B |
